Bioventus (BVS) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Maintained | Overweight | $15.00 | Aug 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $19.00 from $15.00 | Aug 17, 2026 |
| Barrington Research | Maintained | Outperform | $14.00 | Jun 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $15.00 | Jun 16, 2026 |
| Barrington Research | Maintained | Outperform | $14.00 | May 22, 2026 |
| Craig-Hallum | Maintained | Buy | $16.00 from $15.00 | Mar 6, 2026 |
| Barrington Research | Maintained | Outperform | $14.00 from $13.00 | Mar 6, 2026 |
| Barrington Research | Initiated Coverage | Outperform | $13.00 | Feb 9, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $12.00 | Jul 7, 2025 |
| Canaccord Genuity | Maintained | Buy | $15.00 | Mar 17, 2025 |
| JP Morgan | Upgraded | Underweight → Neutral | $13.00 from $12.00 | Dec 17, 2024 |
| Canaccord Genuity | Maintained | Buy | $15.00 from $12.00 | Nov 6, 2024 |
| Craig-Hallum | Maintained | Buy | $17.00 from $12.00 | Sep 27, 2024 |
| Canaccord Genuity | Maintained | Buy | $12.00 from $8.00 | Aug 13, 2024 |
| Craig-Hallum | Maintained | Buy | $12.00 from $9.00 | Aug 7, 2024 |
| Canaccord Genuity | Maintained | Buy | $8.00 from $7.00 | May 8, 2024 |
| Craig-Hallum | Maintained | Buy | $9.00 from $6.00 | Mar 13, 2024 |
| Canaccord Genuity | Upgraded | Hold → Buy | $7.00 from $3.66 | Dec 7, 2023 |
| Craig-Hallum | Maintained | Hold | $5.00 from $10.00 | Apr 3, 2023 |
Frequently asked questions
What is the price target for BVS stock?
The average 12-month analyst price target for Bioventus (BVS) is $16.00, with a high estimate of $19.00 and a low of $14.00, across 3 analysts.
Is BVS a buy, sell, or hold?
Analysts covering Bioventus currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BVS?
The average price target of $16.00 implies 17.22% upside from the last price of $13.65.
What is the latest analyst rating on BVS?
On Aug 17, 2026, Cantor Fitzgerald maintained Bioventus at Overweight with a price target of $15.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.